Developer docs
API playgroundTry for free, no card

Search company profiles

CanSinoBIO

Full company profile

uuid00052ei

Namestring
CanSinoBIO
Legal namestring
CanSino Biologics Inc.
Websiteurl
cansinotech.com
Company typeenum
Public
Founded yearint
2009
Descriptiontext

CanSino Biologics Inc. (CanSinoBIO) is a Chinese biopharmaceutical company founded in 2009 and dual-listed on the Shanghai STAR Market (688185.SH) and the Hong Kong Stock Exchange (06185.HK), headquartered in Tianjin with additional operations in Beijing, Shanghai, Hong Kong, Toronto, and Singapore. The company develops, manufactures, and commercializes vaccines for human use, with six launched products built on five proprietary technology platforms: adenovirus Type 5 viral vector, synthetic biotechnology, protein structure design and VLP assembly, mRNA/LNP, and formulation/drug delivery. Marketed products include Convidecia and Convidecia Air (COVID-19 vaccines, including the world's first inhaled adenoviral vector COVID-19 vaccine), Menhycia (Asia's first MCV4 meningococcal conjugate vaccine), Menphecia (bivalent meningococcal conjugate vaccine), iPneucia (China's first dual-carrier PCV13 pneumococcal vaccine), and Tripedia (China's first three-component DTcP combination vaccine for infants). The pipeline includes PCV24, Td5cp (adolescent/adult pertussis), an inhaled tuberculosis vaccine, a recombinant polio vaccine backed by the Bill & Melinda Gates Foundation, and an mRNA multivalent influenza vaccine.

CanSinoBIO generates revenue through vaccine product sales across China's dual-track vaccine market — large-volume, price-regulated procurement under the National Immunization Program alongside a growing private-pay segment for adult boosters and novel platforms. The company employs a unique Direct Sales and Sales Agency Model with commercial access to 31 provinces in China, supported by a Commercial Operation Center (COC). Internationally, the company pursues regulatory approvals and localization partnerships in 15+ countries across Southeast Asia, the Middle East, North Africa, Latin America, and Eastern Europe. Full-year 2025 revenue reached RMB 1.068 billion (~USD 148M), representing 26.18% year-on-year growth, with net profit of RMB 27.87 million marking a return to profitability after a 2024 net loss. The customer base spans Chinese national immunization programs, international governments (Indonesia, Morocco), and regional pharmaceutical partners (Etana, Solution Group, SPIMACO).

Short descriptiontext

CanSinoBIO is a Chinese biopharmaceutical company developing, manufacturing, and commercializing innovative vaccines across five proprietary technology platforms, serving government immunization programs and private-pay markets in China and 15+ international markets with six launched products including MCV4, PCV13, DTcP, and COVID-19 vaccines.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersTianjin, China
HQ citystring
Tianjin
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
vaccine development, infectious disease prevention, biopharmaceutical manufacturing, conjugate vaccines, viral vector vaccines
Industry4 codes
PRIMARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAJ
Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAK
Vaccine Cold Chain, Storage & Distribution
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Human Vaccines
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Vaccine Product Sales
TypeOne Time License
Description

CanSinoBIO generates revenue primarily through sales of its launched vaccine products including Convidecia, Convidecia Air, Menhycia, Menphecia, iPneucia, and Tripedia. The company reported full-year 2025 revenue of RMB 1.068 billion representing 26.18% year-on-year growth.

cansinotech.com
2National Immunization Program (NIP) Public Procurement
TypeOne Time License
Description

China's vaccine market operates under a dual-track system with large-volume, price-regulated public procurement for the National Immunization Program alongside a growing private-pay market for adult boosters and novel platforms.

indexbox.io
3Private Pay Market
TypeOne Time License
Description

Growing private-pay market for adult boosters and novel vaccine platforms. Private market sales for innovative vaccines not included in the national immunization program.

indexbox.io
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Infrastructure, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Tripecia®
Description

Three-Component DTcP Vaccine (adsorbed diphtheria, tetanus and pertussis (acellular, three component) combined vaccine) — first approved DTcP vaccine in China for infants.

cansinotech.com
+5 more records
Core offering1 text field

CanSinoBIO is an industry-leading biopharmaceutical company that researches, develops, manufactures, and commercializes innovative vaccines for human use targeting infectious diseases. The company markets six products spanning meningococcal (Menhycia, Menphecia), pneumococcal (iPneucia), pertussis-based DTcP (Tripieza), and COVID-19 (Convidecia, Convidecia Air) vaccines, built on five proprietary technology platforms including adenovirus-based viral vector, synthetic biotechnology, protein structure design and VLP assembly, mRNA/LNP, and formulation/drug delivery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 14-day protection efficacy: 68.83% effective in preventing all symptomatic COVID-19 disease and 95.47% effective in preventing severe COVID-19 disease
+3 more records
Product overview1 text field

CanSinoBIO is an industry-leading biopharmaceutical company offering a diversified portfolio of innovative vaccines for human use. The company has launched 6 marketed products built on 5 technology platforms (adenovirus-based viral vector, synthetic biotechnology, protein structure design/VLP assembly, mRNA/LNP, and formulation/delivery). The portfolio includes: Tripieza (first-in-class DTcP vaccine for infants), Menhycia (Asia's first MCV4 meningococcal vaccine), iPneucia (first dual-carrier PCV13), Menphecia (bivalent meningococcal vaccine), Convidecia (adenovirus vector COVID-19 vaccine, WHO EUL), and Convidecia Air (world's first inhaled COVID-19 vaccine). The pipeline includes PCV24, Td5cp, inhaled tuberculosis vaccine, recombinant polio vaccine, and mRNA influenza vaccine.

Product and service6 records
1Convidecia
CategoryCOVID-19 Vaccine
Description

Recombinant COVID-19 Vaccine using Adenovirus Type 5 Vector. Single-dose vaccine providing humoral and cellular immunity. WHO Emergency Use Listed and conditionally approved by China NMPA.

2Convidecia Air
CategoryCOVID-19 Vaccine (Inhaled)
Description

World's first aerosolized recombinant viral vector COVID-19 vaccine for inhalation. Needle-free, providing triple comprehensive protection including mucosal immunity without intramuscular injection, leveraging the same adenovirus vector technological platform as Convidecia.

3Menhycia
CategoryMeningococcal Vaccine
Description

Group ACYW135 Meningococcal Conjugate Vaccine using CRM197 carrier protein. China's first-in-class and first NDA approved MCV4 vaccine covering serogroups A, C, Y, and W135. Indicated for infants and children aged 3 months to 6 years.

4Menphecia
CategoryMeningococcal Vaccine
Description

Group A and Group C Meningococcal Conjugate Vaccine using CRM197 carrier protein. China best-in-class bivalent meningococcal vaccine competing with domestic MCV2 products commercialized by well-known manufacturers in China.

5iPneucia
CategoryPneumococcal Vaccine
Description

13-Valent pneumococcal polysaccharide conjugate vaccine (PCV13*i) using dual-carrier conjugation technology with CRM197 and tetanus toxoid (TT). China's first pneumococcal conjugate vaccine with dual-carrier technology, approved for children aged 6 weeks to 5 years, exhibiting enhanced immunogenicity against serotypes 19F, 19A, 7F, and 3.

6Tripeza
CategoryPertussis Combination Vaccine
Description

Three-Component DTcP Vaccine (adsorbed diphtheria, tetanus and pertussis acellular vaccine) for infants. Contains pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN) antigens. First-in-class approved DTcP vaccine in China.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Beijing Institute of Biotechnology
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-developed Convidecia recombinant COVID-19 vaccine with the Beijing Institute of Biotechnology, Academy of Military Medical Sciences. Previously jointly developed the recombinant Ebola vaccine approved in China in 2017.

cansinotech.com
2Etana (Indonesia)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Tripartite cooperation agreement on inhaled tuberculosis vaccine development. CanSinoBIO and Indonesian Biopharmaceutical Company Etana collaborating on TB vaccine development and commercialization in Indonesia.

cansinotech.com
3Solution Group Berhad (Malaysia)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Signed share subscription agreement for vaccine fill-and-finish facilities development. Collaboration includes mRNA multivalent influenza vaccine development with local institutions in Malaysia.

cansinotech.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Signed cooperation framework agreement on innovative vaccine with Saudi Arabia's pharmaceutical manufacturing company. Exploring joint R&D and localized production opportunities in the Middle East.

Strategic tierSupportingTypeTechnology or Integration
Description

International R&D partnership enhancing innovative capabilities through collaboration with prominent research organizations worldwide.

Strategic tierSupportingTypeTechnology or Integration
Description

International R&D partnership for vaccine development and technology advancement.

Strategic tierSupportingTypeTechnology or Integration
Description

R&D collaboration partnership with Vaccitech for vaccine technology development.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Joint training programs with Peking University to cultivate emerging young professionals equipped for competitive environment in biotechnology.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Joint training programs with Nankai University for talent development in biotechnology and vaccine research.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

mRNA platform vaccine leader with COVID, RSV, influenza, and emerging pipeline products. Comparable through CanSinoBIO's mRNA/LNP platform ambitions and overlap in respiratory and combination vaccine development.

TypeEmerging player
Description

India-based emerging-market vaccine specialist with broad portfolio including rotavirus (ROTAVAC), typhoid conjugate, and COVID vaccines. Comparable as an emerging-market champion targeting infectious disease tenders and WHO PQ, with similar platform diversification ambitions.

3Sinovac Biotech
TypeDirect peer
Description

Beijing-based vaccine developer with a comparable portfolio spanning COVID-19 (CoronaVac), influenza, enterovirus, and hepatitis vaccines. Closest analog to CanSinoBIO in terms of Chinese origin, WHO-listed COVID vaccine, and emerging-market export focus.

TypeDirect peer
Description

Kunming-headquartered Chinese vaccine maker with meningococcal, pneumococcal, HPV, and influenza products. Direct competitor in bivalent meningococcal and PCV13 markets where CanSinoBIO's Menphecia and iPneucia compete.

TypeBroad incumbent
Description

Global top-tier vaccine developer with Menveo/MenQuadfi (meningococcal), Bexsero/Shingrix portfolios, and large pediatric NIP presence. Comparable as an incumbent CanSinoBIO competes against in emerging-market MCV4 tenders and combination-vaccine development.

TypeEmerging player
Description

Largest vaccine manufacturer by doses globally, supplying low-cost NIP vaccines across emerging markets. Comparable in scale-driven emerging-market export model and WHO PQ-eligible pneumococcal, meningococcal, and polio products that compete with CanSinoBIO.

7China National Biotec Group (Sinopharm)
TypeBroad incumbent
Description

State-owned largest Chinese vaccine manufacturer offering a broad NIP portfolio (polio, measles, hepatitis, influenza, COVID). Direct competitor for NIP tenders and emerging-market supply contracts that CanSinoBIO is targeting.

TypeEmerging player
Description

US-listed protein subunit / VLP platform vaccine developer (Nuvaxovid COVID vaccine, R21/Matrix-M malaria). Comparable in platform-based approach, including VLP/Matrix-adjuvant technology, though at a different stage of commercial maturity.

9Sanofi Pasteur
TypeBroad incumbent
Description

Global vaccine franchise spanning influenza, meningococcal (MenQuadfi), pediatric combinations (Hexaxim/Vaxelis), and PCV (nirsevimab-adjacent programs). Comparable as a broad incumbent competing in NIP and private-pay markets CanSinoBIO targets.

TypeDirect peer
Description

Chinese-listed vaccine major distributing Merck's PCV13/PCV15 and operating domestic ACYW135 meningococcal franchise. Competes head-to-head with CanSinoBIO's Menhycia and iPneucia on NIP and private-pay channels.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CanSinoBIO

Human Vaccinescansinotech.com

CanSinoBIO is a Chinese biopharmaceutical company developing, manufacturing, and commercializing innovative vaccines across five proprietary technology platforms, serving government immunization programs and private-pay markets in China and 15+ international markets with six launched products including MCV4, PCV13, DTcP, and COVID-19 vaccines.

What CanSinoBIO does

CanSino Biologics Inc. (CanSinoBIO) is a Chinese biopharmaceutical company founded in 2009 and dual-listed on the Shanghai STAR Market (688185.SH) and the Hong Kong Stock Exchange (06185.HK), headquartered in Tianjin with additional operations in Beijing, Shanghai, Hong Kong, Toronto, and Singapore. The company develops, manufactures, and commercializes vaccines for human use, with six launched products built on five proprietary technology platforms: adenovirus Type 5 viral vector, synthetic biotechnology, protein structure design and VLP assembly, mRNA/LNP, and formulation/drug delivery. Marketed products include Convidecia and Convidecia Air (COVID-19 vaccines, including the world's first inhaled adenoviral vector COVID-19 vaccine), Menhycia (Asia's first MCV4 meningococcal conjugate vaccine), Menphecia (bivalent meningococcal conjugate vaccine), iPneucia (China's first dual-carrier PCV13 pneumococcal vaccine), and Tripedia (China's first three-component DTcP combination vaccine for infants). The pipeline includes PCV24, Td5cp (adolescent/adult pertussis), an inhaled tuberculosis vaccine, a recombinant polio vaccine backed by the Bill & Melinda Gates Foundation, and an mRNA multivalent influenza vaccine.

CanSinoBIO generates revenue through vaccine product sales across China's dual-track vaccine market — large-volume, price-regulated procurement under the National Immunization Program alongside a growing private-pay segment for adult boosters and novel platforms. The company employs a unique Direct Sales and Sales Agency Model with commercial access to 31 provinces in China, supported by a Commercial Operation Center (COC). Internationally, the company pursues regulatory approvals and localization partnerships in 15+ countries across Southeast Asia, the Middle East, North Africa, Latin America, and Eastern Europe. Full-year 2025 revenue reached RMB 1.068 billion (~USD 148M), representing 26.18% year-on-year growth, with net profit of RMB 27.87 million marking a return to profitability after a 2024 net loss. The customer base spans Chinese national immunization programs, international governments (Indonesia, Morocco), and regional pharmaceutical partners (Etana, Solution Group, SPIMACO).

CanSinoBIO firmographics

Firmographics
Name
CanSinoBIO
Legal name
CanSino Biologics Inc.
Website
https://cansinotech.com
Company type
Public
Founded year
2009
Operating status
Operating
Headcount range
101–250 employees
Short description
CanSinoBIO is a Chinese biopharmaceutical company developing, manufacturing, and commercializing innovative vaccines across five proprietary technology platforms, serving government immunization programs and private-pay markets in China and 15+ international markets with six launched products including MCV4, PCV13, DTcP, and COVID-19 vaccines.
Ownership category
akta.pro rank

CanSinoBIO industry classification

Industry
Product category
Human Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAJ
Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAK
Vaccine Cold Chain, Storage & Distribution

Keywords

  • Vaccine development
  • Infectious disease prevention
  • Biopharmaceutical manufacturing
  • Conjugate vaccines
  • Viral vector vaccines

Where CanSinoBIO is headquartered

Location

Headquarters

HQ city
Tianjin
HQ country
China
HQ region
Asia

Offices8 records

Markets served

CanSinoBIO business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Infrastructure, Personnel, Marketing or Sales, Operations

Revenue model

  1. Vaccine Product Sales: CanSinoBIO generates revenue primarily through sales of its launched vaccine products including Convidecia, Convidecia Air, Menhycia, Menphecia, iPneucia, and Tripedia. The company reported full-year 2025 revenue of RMB 1.068 billion representing 26.18% year-on-year growth.
  2. National Immunization Program (NIP) Public Procurement: China's vaccine market operates under a dual-track system with large-volume, price-regulated public procurement for the National Immunization Program alongside a growing private-pay market for adult boosters and novel platforms.
  3. Private Pay Market: Growing private-pay market for adult boosters and novel vaccine platforms. Private market sales for innovative vaccines not included in the national immunization program.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

CanSinoBIO product offering

Product offering

Core offering

CanSinoBIO is an industry-leading biopharmaceutical company that researches, develops, manufactures, and commercializes innovative vaccines for human use targeting infectious diseases. The company markets six products spanning meningococcal (Menhycia, Menphecia), pneumococcal (iPneucia), pertussis-based DTcP (Tripieza), and COVID-19 (Convidecia, Convidecia Air) vaccines, built on five proprietary technology platforms including adenovirus-based viral vector, synthetic biotechnology, protein structure design and VLP assembly, mRNA/LNP, and formulation/drug delivery.

Product overview

CanSinoBIO is an industry-leading biopharmaceutical company offering a diversified portfolio of innovative vaccines for human use. The company has launched 6 marketed products built on 5 technology platforms (adenovirus-based viral vector, synthetic biotechnology, protein structure design/VLP assembly, mRNA/LNP, and formulation/delivery). The portfolio includes: Tripieza (first-in-class DTcP vaccine for infants), Menhycia (Asia's first MCV4 meningococcal vaccine), iPneucia (first dual-carrier PCV13), Menphecia (bivalent meningococcal vaccine), Convidecia (adenovirus vector COVID-19 vaccine, WHO EUL), and Convidecia Air (world's first inhaled COVID-19 vaccine). The pipeline includes PCV24, Td5cp, inhaled tuberculosis vaccine, recombinant polio vaccine, and mRNA influenza vaccine.

Differentiator

Problem solved

Functional benefit

Brands

  • Tripecia®: Three-Component DTcP Vaccine (adsorbed diphtheria, tetanus and pertussis (acellular, three component) combined vaccine) — first approved DTcP vaccine in China for infants.
  • Menhycia®
  • Menphecia®
  • iPneucia®
  • Convidecia®
  • Convidecia Air®

Products and services

  • Convidecia Recombinant COVID-19 Vaccine using Adenovirus Type 5 Vector. Single-dose vaccine providing humoral and cellular immunity. WHO Emergency Use Listed and conditionally approved by China NMPA.
  • Convidecia Air World's first aerosolized recombinant viral vector COVID-19 vaccine for inhalation. Needle-free, providing triple comprehensive protection including mucosal immunity without intramuscular injection, leveraging the same adenovirus vector technological platform as Convidecia.
  • Menhycia Group ACYW135 Meningococcal Conjugate Vaccine using CRM197 carrier protein. China's first-in-class and first NDA approved MCV4 vaccine covering serogroups A, C, Y, and W135. Indicated for infants and children aged 3 months to 6 years.
  • Menphecia Group A and Group C Meningococcal Conjugate Vaccine using CRM197 carrier protein. China best-in-class bivalent meningococcal vaccine competing with domestic MCV2 products commercialized by well-known manufacturers in China.
  • iPneucia 13-Valent pneumococcal polysaccharide conjugate vaccine (PCV13*i) using dual-carrier conjugation technology with CRM197 and tetanus toxoid (TT). China's first pneumococcal conjugate vaccine with dual-carrier technology, approved for children aged 6 weeks to 5 years, exhibiting enhanced immunogenicity against serotypes 19F, 19A, 7F, and 3.
  • Tripeza Three-Component DTcP Vaccine (adsorbed diphtheria, tetanus and pertussis acellular vaccine) for infants. Contains pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN) antigens. First-in-class approved DTcP vaccine in China.

Quantifiable outcome

  • 14-day protection efficacy: 68.83% effective in preventing all symptomatic COVID-19 disease and 95.47% effective in preventing severe COVID-19 disease
  • +3 more outcomes

Companies that use CanSinoBIO

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles3 records

CanSinoBIO technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

CanSinoBIO partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, major and supporting.

  • Beijing Institute of BiotechnologycoreStrategic or Co-development PartnerCo-developed Convidecia recombinant COVID-19 vaccine with the Beijing Institute of Biotechnology, Academy of Military Medical Sciences. Previously jointly developed the recombinant Ebola vaccine approved in China in 2017.
  • Etana (Indonesia)majorStrategic or Co-development PartnerTripartite cooperation agreement on inhaled tuberculosis vaccine development. CanSinoBIO and Indonesian Biopharmaceutical Company Etana collaborating on TB vaccine development and commercialization in Indonesia.
  • Solution Group Berhad (Malaysia)majorStrategic or Co-development PartnerSigned share subscription agreement for vaccine fill-and-finish facilities development. Collaboration includes mRNA multivalent influenza vaccine development with local institutions in Malaysia.
  • SPIMACO (Saudi Arabia)majorStrategic or Co-development PartnerSigned cooperation framework agreement on innovative vaccine with Saudi Arabia's pharmaceutical manufacturing company. Exploring joint R&D and localized production opportunities in the Middle East.
  • National Research Council CanadasupportingTechnology or IntegrationInternational R&D partnership enhancing innovative capabilities through collaboration with prominent research organizations worldwide.
  • BIRD-CsupportingTechnology or IntegrationInternational R&D partnership for vaccine development and technology advancement.
  • VaccitechsupportingTechnology or IntegrationR&D collaboration partnership with Vaccitech for vaccine technology development.
  • Peking UniversitysupportingStrategic or Co-development PartnerJoint training programs with Peking University to cultivate emerging young professionals equipped for competitive environment in biotechnology.
  • Nankai UniversitysupportingStrategic or Co-development PartnerJoint training programs with Nankai University for talent development in biotechnology and vaccine research.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

CanSinoBIO competitors and assessment

Company assessment

Broad incumbents

  • Moderna: mRNA platform vaccine leader with COVID, RSV, influenza, and emerging pipeline products. Comparable through CanSinoBIO's mRNA/LNP platform ambitions and overlap in respiratory and combination vaccine development.
  • GSK Vaccines: Global top-tier vaccine developer with Menveo/MenQuadfi (meningococcal), Bexsero/Shingrix portfolios, and large pediatric NIP presence. Comparable as an incumbent CanSinoBIO competes against in emerging-market MCV4 tenders and combination-vaccine development.
  • China National Biotec Group (Sinopharm): State-owned largest Chinese vaccine manufacturer offering a broad NIP portfolio (polio, measles, hepatitis, influenza, COVID). Direct competitor for NIP tenders and emerging-market supply contracts that CanSinoBIO is targeting.
  • Sanofi Pasteur: Global vaccine franchise spanning influenza, meningococcal (MenQuadfi), pediatric combinations (Hexaxim/Vaxelis), and PCV (nirsevimab-adjacent programs). Comparable as a broad incumbent competing in NIP and private-pay markets CanSinoBIO targets.

Emerging players

  • Bharat Biotech: India-based emerging-market vaccine specialist with broad portfolio including rotavirus (ROTAVAC), typhoid conjugate, and COVID vaccines. Comparable as an emerging-market champion targeting infectious disease tenders and WHO PQ, with similar platform diversification ambitions.
  • Serum Institute of India: Largest vaccine manufacturer by doses globally, supplying low-cost NIP vaccines across emerging markets. Comparable in scale-driven emerging-market export model and WHO PQ-eligible pneumococcal, meningococcal, and polio products that compete with CanSinoBIO.
  • Novavax: US-listed protein subunit / VLP platform vaccine developer (Nuvaxovid COVID vaccine, R21/Matrix-M malaria). Comparable in platform-based approach, including VLP/Matrix-adjuvant technology, though at a different stage of commercial maturity.

Direct peers

  • Sinovac Biotech: Beijing-based vaccine developer with a comparable portfolio spanning COVID-19 (CoronaVac), influenza, enterovirus, and hepatitis vaccines. Closest analog to CanSinoBIO in terms of Chinese origin, WHO-listed COVID vaccine, and emerging-market export focus.
  • Walvax Biotechnology: Kunming-headquartered Chinese vaccine maker with meningococcal, pneumococcal, HPV, and influenza products. Direct competitor in bivalent meningococcal and PCV13 markets where CanSinoBIO's Menphecia and iPneucia compete.
  • Zhifei Biological Products: Chinese-listed vaccine major distributing Merck's PCV13/PCV15 and operating domestic ACYW135 meningococcal franchise. Competes head-to-head with CanSinoBIO's Menhycia and iPneucia on NIP and private-pay channels.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

CanSinoBIO financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CanSinoBIO leadership team

Management profile

Number of profiles

Profiles4 records

CanSinoBIO subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

CanSinoBIO funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CanSinoBIO M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CanSinoBIO

What does CanSinoBIO do?

CanSinoBIO is an industry-leading biopharmaceutical company that researches, develops, manufactures, and commercializes innovative vaccines for human use targeting infectious diseases. The company markets six products spanning meningococcal (Menhycia, Menphecia), pneumococcal (iPneucia), pertussis-based DTcP (Tripieza), and COVID-19 (Convidecia, Convidecia Air) vaccines, built on five proprietary technology platforms including adenovirus-based viral vector, synthetic biotechnology, protein structure design and VLP assembly, mRNA/LNP, and formulation/drug delivery.

Is CanSinoBIO a public or private company?

CanSinoBIO is a public company. It is classified as public and is currently operating.

When was CanSinoBIO founded?

CanSinoBIO was founded in 2009. It employs 101 to 250 people.

Where is CanSinoBIO based?

CanSinoBIO is headquartered in Tianjin, China, in the Asia region.

How does CanSinoBIO make money?

Three revenue lines are on record. Vaccine Product Sales are the primary driver. The others are national Immunization Program (NIP) Public Procurement and private Pay Market.

Who are CanSinoBIO's main competitors?

Broad incumbents on record are Moderna, GSK Vaccines, China National Biotec Group (Sinopharm) and Sanofi Pasteur. Emerging players are Bharat Biotech, Serum Institute of India and Novavax. Direct peers are Sinovac Biotech, Walvax Biotechnology and Zhifei Biological Products.

Does CanSinoBIO have an API?

No public API is recorded for CanSinoBIO.

What industry is CanSinoBIO in?

CanSinoBIO's product category is Human Vaccines. Its primary akta.pro industry code is HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens), with a secondary code of HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MoomooZhitong Stock Connect Active Trading | November 16On November 16, 2026, Alibaba-W led Shanghai-HK Stock Connect turnover at RMB 2.908 billion, while Tencent led Shenzhen-HK at RMB 1.543 billion. CanSino Biologics and Zhipu ranked second and third in Shanghai-HK, with net purchases or sales varying by stock.MoomooKindstar Global (09960) repurchased 23,000 shares for approximately HKD 20,100 on November 12.On November 12, 2026, CanSino Biologics repurchased 23,000 shares at a cost of approximately HKD 20,100, with prices ranging from HKD 0.865 to HKD 0.895 per share. The repurchase was announced by the company.JiemianHong Kong Stock Market Midday Review: Hang Seng Index up 0.2%, Hang Seng Tech Index up 0.07%On November 9, the Hong Kong stock market closed at noon with the Hang Seng Index up 0.2% and the Hang Seng Technology Index up 0.07%. Biotechnology stocks led gains, with Zai Lab rising over 13% and CanSino Biologics nearly 5%, while physical AI concept stocks also advanced.Business & FinancialCansinobio Reports Growth In First Nine Months: Commercialization Accelerates Across Multiple Products As Platform Innovation Opens New Avenues For GrowthCanSino Biologics reported Q3 2026 revenue of RMB 882 million, up 27.4% year-on-year, with net profit of RMB 16.29 million. The company launched Tripecia(R) and Tetcia(R) vaccines and advanced international partnerships, including an mRNA collaboration with deepGeneAI.The future of tradingCanSinoBIO Reports Positive Primary Immunization Data From Phase II Polio Vaccine TrialCanSinoBIO reported positive primary immunization data from key groups in its Phase II VLP-Polio vaccine trial in Indonesia, supporting further development. The vaccine does not require infectious live poliovirus in production, reducing the risk of viral release during manufacturing.American Banking and Market NewsCanSino Biologics (OTCMKTS:CASBF) Stock Price Down 19.4% – What’s Next?CanSino Biologics' stock fell 19.4% to C$3.95 during mid-day trading on Thursday, with volume up 56% to about 1,000 shares. The company, a China-based biotech, develops vaccines including Convidecia and Convidecia Air.JiemianHong Kong Stock Midday Review: Hang Seng Index rises by 1.21%, Hang Seng Tech Index rises by 2.09%On October 16, the Hang Seng Index rose 1.21% and the Hang Seng Tech Index rose 2.09% at noon. Pharmaceutical stocks led gains, with Cloudmed and CanSino up over 8%, while AI stocks like Inspur and Aisino rose over 6%.JiemianThe Hang Seng Index and the Hang Seng Tech Index both rose by about 1%, with pharmaceutical and biotechnology stocks climbing.Hong Kong stocks closed higher, with the Hang Seng Index rising 1% and the Hang Seng Tech Index rising 0.94%. Pharmaceutical and biotechnology stocks led gains, with CanSino Biologics up over 14% and GLM-5.3 launched on Amazon Bedrock.The future of tradingCanSinoBIO CEO Yu attends World Economic Forum Sustainable Development Impact Meetings in New YorkCanSinoBIO CEO Xuefeng Yu attended the World Economic Forum's Sustainable Development Impact Meetings in New York on Sept. 21-24. First-half revenue totaled RMB 550 million, up 43.8% year on year, and overseas revenue reached RMB 152 million. Menhycia, a quadrivalent meningococcal conjugate vaccine, won marketing authorization in Indonesia and Argentina.YicaiglobalConnecting Innovation and Global Markets: Jeanne Wang on CanSinoBIO’s Next Stage of GrowthCanSinoBIO reported H1 2026 revenue of RMB550 million, up 43.8% year on year, with overseas revenue of RMB152 million. CEO Jeanne Wang said the company's next stage focuses on integrating innovation with market needs, including portfolio expansion and international partnerships.